News

According to the company, the initial indications for AMPLEX and PREFIX to be investigated are fusion in foot/ankle and lumbar spine surgical procedures, respectively. The two products are

Resolaris is being developed as a first-in-class intravenous protein therapeutic to treat rare myopathies with an immune component. The drug represents the company’s first Physiocrine-based product candidate in

In June 2006, Revlimid plus dexamethasone was approved for use in multiple myeloma patients who have received at least one prior therapy. The approval of Revlimid was based

Under the deal, Teva will be responsible for all US commercial activities for the product including promotion and distribution, while Eagle’s responsibility include securing all regulatory approvals, conducting

The research collaboration and license agreement will see new small-molecule therapies directed against the nuclear hormone receptors called ROR gamma (t) to treat these disorders. As part of

Under the deal, Celon will supply the product to Lupin, which will be responsible for its commercialization in the US, Canada, Mexico and other key markets. GSK’s Advair

Under the deal, Agilvax will use Humabs’ antibodies developed from patient survivors of infectious and chronic diseases. The collaboration will contribute to the rapid advancement of Agilvax’s expanding

Lightlake is focused on developing addiction treatments based on its expertise in opioid antagonists. In December 2014, Lightlake in partnership with the National Institute on Drug Abuse (NIDA),

The company noted that the FDA approved prescription treatment option is now available in pharmacies nationwide for patients with rosacea, a common, inflammatory disorder affecting the face. The